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SUPPRESS ALLOANTIGEN-STIMULATED IMMUNE CELLS IN VITRO
Erkers, T.1, Nava, S.1, Ruhm, S.1, Westgren, M.2, Ringden, O.1,
Karlsson, H.1 1Karolinska Institutet, Stockholm, Sweden; 2Karolinska In-
stitutet, Stockholm, Sweden
Bone marrow-derived mesenchymal stromal cells (BM-MSC)
have been used to treat steroid refractory acute GVHD, but there
are indications that stromal cells isolated from term placental tissue
have a stronger immunosuppressive effect in vitro. Unlike BM-MSC,
these cells are accessible with non-invasive procedures and require
little or no ethical consideration. We have isolated stromal cells
from term fetal membrane (FMSCs), umbilical cords (UCSCs),
and placental villi (PVSCs) as well as from bone marrow and com-
pared their immunoregulatory capacity in allogeneic settings. Pe-
ripheral blood mononuclear cells (PBMC) from at least 16 donors
were stimulated with irradiated allogeneic PBMC in mixed lympho-
cyte reactions (MLRs) in the absence or presence of stromal cells
(stromal cells/PBMC ratio 1:10). FMSC showed the strongest and
most consistent suppression (median 47% suppression, P\0.0001)
compared to UCSCs (29%, P 5 0.015) and BM-MSCs (41%, P 5
0.014), whereas PVSCs showed poor suppressive capacity. We fur-
ther found that crude preparations of unseparated fetal membrane
generated stromal cells that were at least as good at depriving prolif-
eration compared to cells isolated from separated amniotic or cho-
rionic membranes. When the FMSC were pre-cultured for 48h in
MLR supernatants, the inhibiting effect on proliferation of the
MLR cultures was increased (P5 0.031). FMSC also reduced prolif-
eration of T-cells when added to cultures of anti-CD3 and -CD28
stimulated purified CD3+ cells (median 49% suppression). When
added to MLR cultures, FMSCs suppressed the production of
IFN-g and IL-17 (P 5 0.0013 and P 5 0.03, respectively), but pro-
moted the secretion of IL-10 (P 5 0.0071). In this setting, BM-
MSCs had no significant effect on secretion of IFN-g, IL-17, or
IL-10. Surface expression analysis with flow cytometry showed
that FMSCs had a higher expression of adhesion molecules ICAM-
1, CD29 (b1), and CD49d (a4) (P\0.05), and of the negative costi-
mulatory marker PD-L1 (P\0.05), compared to BM-MSC. Both
FMSC and BM-MSC showed high expression of PD-L2. To con-
clude, FMSC may have therapeutic potential in inflammatory disor-
ders such as GVHD, as they greatly suppress T-cells in allogeneic
settings and express high levels of integrins that are of importance
in homing to inflamed tissues.164
MULTIPOTENT ADULT PROGENITOR CELLS (MULTISTEM) ENHANCE
BONE MARROW RECOVERY AFTER ABLATIVE ALLOGENEIC STEM CELL
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Adherent stem cells, exemplified by mesenchymal stromal cells
(MSC), are being increasingly evaluated in the hematopoietic stem
cell transplant (HSCT) setting as a potential means to prevent or
ameliorate acute graft-versus-host-disease. Anecdotal data suggest
MSC can support hematopoiesis after HSCT. The potential role
of MSC to enhance hematopoiesis is also being investigated, partic-
ularly with ex vivo expansion of low dose stem cell donors such as
cord blood. However, the effect of infusedMSC on bonemarrow re-
covery after ablative HSCT remains unclear.
A matched cohort analysis was performed comparing patients in
a Phase I dose-escalation trial evaluating maximum-tolerated single
or repeated dose of allogeneic Multistem, an adherent multipotent
adult progenitor cell (MAPC) product, with a control population un-
dergoing HSCT without MAPC administration. Patients surviving
at least 50 days post-HSCT without relapse were eligible for analy-
sis, and matched with a control cohort by disease and transplantS264characteristics. Time to neutrophil (ANC$500/ul for 3 consecutive
days) and platelet (sustained platelets $50,000 without transfusion)
engraftment, as well as total bone marrow cellularity after HSCT
on days 28 and 100 by blinded double pathologist independent re-
view, were assessed. Unpaired t test was applied to compare days
of engraftment and marrow cellularities.
23 patients undergoing conventional ablative allogeneic HSCT
with MAPC exposure in addition to their matched pair allogeneic
HSCT recipients were eligible for analysis (Table 1). The median
time to neutrophil engraftment was significantly shortened among
patients receiving MAPC, compared to control patients, occurring
at day 14 (range 11-23) and 17 (range 13-23), respectively (p 5
0.016). There was no significant difference in time to platelet en-
graftment. In 16/23 (70%) and 10/14 (71%) evaluable patients re-
ceiving MAPC, total marrow cellularity was $ control patients at
days 28 and 100. There was a trend towards significantly increased
marrow cellularity at these time points among recipients of MAPC
(p 5 0.077 and p 5 0.061).
The infusion of MAPC progenitors in patients receiving alloge-
neic HSCT is associated with a shorter time to neutrophil engraft-
ment. Total bone marrow cellularity at days 28 and 100 appears
enhanced among patients receiving MAPC. These preliminary find-
ings support further analysis of a role for infused MSC in facilitating
bone marrow recovery in the HSCT-setting.
Table 1.
MAPC Recipients Control CohortNumber of Patients 23 23
Age in years 58 (20-63) 53 (24-65)
Gender:
Male 16 21
Female 7 2Disease:
AML 13 8
MDS 4 8
ALL 3 3
CML 1 3
Other 2 1Donor Type:
Related 11 12
Unrelated 12 11Stem Cell Source:
Bone Marrow 0 0
Peripheral Blood 23 23HLA-Match:
Matched 22 21
Single-Antigen Mismatch 1 2Conditioning:
Bu/Cy 9 14
TBI/Cy 5 9
Flu/Mel 9 0GVHD Prophylaxis:
FK506/MTX 23 23165
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Background: MultiStem, multipotent adult progenitor cells
(MAPC), are an immune-modulatory, bone marrow-derived adult
adherent allogeneic stem cell product that can be manufactured to
large scale. This provides consistency of universal donor stromal
cell therapy product during clinical studies. Pre-clinical studies
showed safety of IV infusion and survival benefit in a haploidentical
